Literature DB >> 19399413

Chitosan/pshRNA plasmid nanoparticles targeting MDR1 gene reverse paclitaxel resistance in ovarian cancer cells.

Yan Yang1, Zehua Wang, Minfang Li, Shi Lu.   

Abstract

In order to investigate the effect of chitosan/pshRNA plasmid nanoparticles targeting MDR1 genes on the resistance of A2780/TS cells to paclitaxel, chitosan/pshRNA plasmid nanoparticles were synthesized by means of a complex coacervation technique and transfected into A2780/TS cells. The cells transfected with MDR1-targeted chitosan/pshRNA plasmid nanoparticles were experimental cells and the cells transfected with chitosan/pGPU6/GFP/Neo no-load plasmid nanoparticles served as negative control cells. Morphological features of the nanoparticles were observed under transmission electron microscope (TEM). MDR1 mRNA expression was assessed by RT-PCR. Half-inhibitory concentration (IC50) of paclitaxel for A2780/TS cells was determined by MTT method. TEM showed that the nanoparticles were round-shaped, smooth in surface and the diameters varied from 80 to 120 nm. The MDR1 mRNA in the transfected cells was significantly decreased by 17.6%, 27.8% and 52.6% on the post-transfection day 2, 4 and 7 when compared with that in A2780/TS cells control (P<0.05). MTT assay revealed that the relative reversal efficiency was increased over time and was 29.6%, 51.2% and 61.3% respectively in the transfected cells 2, 4, 7 days after transfection and IC50 (0.197+/-0.003, 0.144+/-0.001, 0.120+/-0.004) were decreased with difference being significant when compared with that in A2780/TS (0.269+/-0.003) cells control (P<0.05). It was concluded that chitosan/pshRNA plasmid nanoparticles targeting MDR1 can effectively reverse the paclitaxel resistance in A2780/TS cells in a time-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19399413     DOI: 10.1007/s11596-009-0221-2

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  25 in total

Review 1.  Chitosans for gene delivery.

Authors:  G Borchard
Journal:  Adv Drug Deliv Rev       Date:  2001-11-05       Impact factor: 15.470

2.  In vitro characterization and delivery of chitosan-DNA microparticles into mammalian cells.

Authors:  Tugce Dastan; Kadir Turan
Journal:  J Pharm Pharm Sci       Date:  2004-06-30       Impact factor: 2.327

3.  Chitosan microparticles containing plasmid DNA as potential oral gene delivery system.

Authors:  Ulker Guliyeva; Filiz Oner; Sule Ozsoy; Rifki Haziroğlu
Journal:  Eur J Pharm Biopharm       Date:  2005-10-27       Impact factor: 5.571

4.  Reversal of adriamycin resistance in human mammary cancer cells by small interfering RNA of MDR1 and MDR3 genes.

Authors:  Lan Xiao; Rui Gao; Shi Lu; Lirong Ren; Zehua Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

Review 5.  RNAi therapeutics: principles, prospects and challenges.

Authors:  Lars Aagaard; John J Rossi
Journal:  Adv Drug Deliv Rev       Date:  2007-03-16       Impact factor: 15.470

Review 6.  Transport proteins of the ABC family and multidrug resistance of tumor cells.

Authors:  A A Stavrovskaya; T P Stromskaya
Journal:  Biochemistry (Mosc)       Date:  2008-05       Impact factor: 2.487

7.  Chitosan-membrane interactions and their probable role in chitosan-mediated transfection.

Authors:  S Venkatesh; T J Smith
Journal:  Biotechnol Appl Biochem       Date:  1998-06       Impact factor: 2.431

8.  Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells.

Authors:  Hao Wu; William N Hait; Jin-Ming Yang
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

Review 9.  Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation.

Authors:  R Z Yusuf; Z Duan; D E Lamendola; R T Penson; M V Seiden
Journal:  Curr Cancer Drug Targets       Date:  2003-02       Impact factor: 3.428

10.  Combination of poly(ethylenimine) and chitosan induces high gene transfection efficiency and low cytotoxicity.

Authors:  Qing-Qing Zhao; Jin-Liang Chen; Min Han; Wen-Quan Liang; Yasuhiko Tabata; Jian-Qing Gao
Journal:  J Biosci Bioeng       Date:  2008-01       Impact factor: 2.894

View more
  5 in total

1.  Reversal of multi-drug resistance by vector-based-shRNA-mdr1 in vitro and in vivo.

Authors:  Shi Lu; Qi Huang; Zehua Wang; Yinfeng Song; Lijun Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-10-11

2.  Evaluation of Chitosan-Tripolyphosphate Nanoparticles as a p-shRNA Delivery Vector: Formulation, Optimization and Cellular Uptake Study.

Authors:  Mahdi Karimi; Pinar Avci; Mohsen Ahi; Tarane Gazori; Michael R Hamblin; Hossein Naderi-Manesh
Journal:  J Nanopharm Drug Deliv       Date:  2013-09-01

Review 3.  Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.

Authors:  Javed Ahmad; Sohail Akhter; Nigel H Greig; Mohammad Amjad Kamal; Patrick Midoux; Chantal Pichon
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

4.  Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.

Authors:  Donavon Hiss
Journal:  J Oncol       Date:  2012-02-06       Impact factor: 4.375

Review 5.  Dendritic cell engineering for selective targeting of female reproductive tract cancers.

Authors:  Arpit Bhargava; Rupesh Kumar Srivastava; Dinesh Kumar Mishra; Rajnarayan R Tiwari; Radhey Shyam Sharma; Pradyumna Kumar Mishra
Journal:  Indian J Med Res       Date:  2018-12       Impact factor: 2.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.